support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program.




Building on years of collaboration, the agreement reflects a shared long-term vision:delivering lower carbon inhaled therapies through CMIs at scale, without compromisingclinical choiceorcontinuity of carefor patients. Both companies are committed to addressingclimate changethrough measurable, science-based action. Chiesi’s ambition to reach Net Zero targets by 2035, and Bespak’s validated decarbonization roadmap, underpin a partnership grounded in shared sustainability principles.

Maria Paola Chiesi,Chiesi Group Vice Chair, said: “At Chiesi,sustainabilityis not an add-on; it is acommitmentthat guides our strategic choices. We know thatinhalersare essential treatments, and that the environmental impact associated with them must be addressed without shifting the burden onto patients. The partnership with Bespak reinforces our efforts to reduce emissions across th
=*=*=*=*=*=
当前为第2/9页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页